Amel Mebazaa, Alain Dupuy, Michel Rybojad, Frédéric Mouly, Isabelle Moulonguet, Marie-Dominique Vignon-Pennamen, Jacqueline Rivet, Anne Janin, Celeste Lebbé, Louis Dubertret, Patrice Morel, Hervé Bachelez, Pauline Brice
{"title":"ESHAP治疗原发性皮肤t细胞淋巴瘤:11例患者的疗效和耐受性","authors":"Amel Mebazaa, Alain Dupuy, Michel Rybojad, Frédéric Mouly, Isabelle Moulonguet, Marie-Dominique Vignon-Pennamen, Jacqueline Rivet, Anne Janin, Celeste Lebbé, Louis Dubertret, Patrice Morel, Hervé Bachelez, Pauline Brice","doi":"10.1038/sj.thj.6200570","DOIUrl":null,"url":null,"abstract":"<p><p>Systemic multiagent hemotherapy has been used to treat aggressive forms of primary cutaneous T-cell lymphomas (CTCL) with controversial results. Our objective was to retrospectively assess efficacy and toxicity of ESHAP (etoposide, cisplatin, high-dose aracytine, methylprednisolone) in patients with advanced CTCL. A total of 11 patients with aggressive primary CTCL, treated with the ESHAP protocol between 1995 and 2002, were studied. Two patients achieved complete remissions lasting 30+ and 6+ months, seven had partial remissions of short duration, one had stable disease and one experienced disease progression. ESHAP was poorly tolerated because of prolonged myelosuppression (91%) and infectious complications (82%). Our results suggest that ESHAP has a poor risk/benefit ratio in advanced CTCL because of the low number of complete remissions, the short duration of partial remissions and its high-grade toxicity.</p>","PeriodicalId":22486,"journal":{"name":"The hematology journal : the official journal of the European Haematology Association","volume":"5 7","pages":"553-8"},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/sj.thj.6200570","citationCount":"8","resultStr":"{\"title\":\"ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients.\",\"authors\":\"Amel Mebazaa, Alain Dupuy, Michel Rybojad, Frédéric Mouly, Isabelle Moulonguet, Marie-Dominique Vignon-Pennamen, Jacqueline Rivet, Anne Janin, Celeste Lebbé, Louis Dubertret, Patrice Morel, Hervé Bachelez, Pauline Brice\",\"doi\":\"10.1038/sj.thj.6200570\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Systemic multiagent hemotherapy has been used to treat aggressive forms of primary cutaneous T-cell lymphomas (CTCL) with controversial results. Our objective was to retrospectively assess efficacy and toxicity of ESHAP (etoposide, cisplatin, high-dose aracytine, methylprednisolone) in patients with advanced CTCL. A total of 11 patients with aggressive primary CTCL, treated with the ESHAP protocol between 1995 and 2002, were studied. Two patients achieved complete remissions lasting 30+ and 6+ months, seven had partial remissions of short duration, one had stable disease and one experienced disease progression. ESHAP was poorly tolerated because of prolonged myelosuppression (91%) and infectious complications (82%). Our results suggest that ESHAP has a poor risk/benefit ratio in advanced CTCL because of the low number of complete remissions, the short duration of partial remissions and its high-grade toxicity.</p>\",\"PeriodicalId\":22486,\"journal\":{\"name\":\"The hematology journal : the official journal of the European Haematology Association\",\"volume\":\"5 7\",\"pages\":\"553-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1038/sj.thj.6200570\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The hematology journal : the official journal of the European Haematology Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/sj.thj.6200570\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The hematology journal : the official journal of the European Haematology Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/sj.thj.6200570","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients.
Systemic multiagent hemotherapy has been used to treat aggressive forms of primary cutaneous T-cell lymphomas (CTCL) with controversial results. Our objective was to retrospectively assess efficacy and toxicity of ESHAP (etoposide, cisplatin, high-dose aracytine, methylprednisolone) in patients with advanced CTCL. A total of 11 patients with aggressive primary CTCL, treated with the ESHAP protocol between 1995 and 2002, were studied. Two patients achieved complete remissions lasting 30+ and 6+ months, seven had partial remissions of short duration, one had stable disease and one experienced disease progression. ESHAP was poorly tolerated because of prolonged myelosuppression (91%) and infectious complications (82%). Our results suggest that ESHAP has a poor risk/benefit ratio in advanced CTCL because of the low number of complete remissions, the short duration of partial remissions and its high-grade toxicity.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
